Ten patients received therapy, with an initial response seen in 7 out of 9 evaluable patients to date. Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.
Dr. Michael K. Schultz, Chief Scientific Officer at Perspective Therapeutics, presented research at the WWIC on the potential of lead-based targeted alpha particle therapy using [212Pb]VMT-α-NET for the treatment of neuroendocrine tumors (NETs)…
“We are pleased with our team’s progress in pioneering the development of promising image-guided, lead-based, alpha particle therapies.” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics…
Our team at Perspective Therapeutics continues to work diligently to advance much needed targeted alpha therapy using 212Pb,” said Thijs Spoor…
First patient with MC1R-positive metastatic melanoma treated with 212Pb-VMT01… Preliminary data readout from dose escalation study expected Q4 2023…
©2023. All rights reserved. Terms & Privacy | Privacy Policy
